Skip to main content

Table 3 Likelihood of implementation of the BPaL (Nix) regimen as standard of care

From: Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients

 

Overall

Indonesia

Kyrgyzstan

Nigeria

n (%)

n (%)

n (%)

n (%)

Implementation of BPaL as the SoC for treatment of XDR-TB and MDR-TB treatment failure/intolerance based on initial profile (Nix)

Total

166

46

50

70

Likely

146 (88%)

40 (87%)

43 (86%)

63 (90%)

Neutral

18 (11%)

6 (13%)

7 (14%)

5 (7%)

Unlikely

2 (1%)

0 (0%)

0 (0%)

2 (3%)

Implementation of BPaL as SoC for treatment of Fq resistant TB without additional resistance to 2nd line injectables based on initial profile (Nix)

Total

169

46

55

68

Likely

142 (84%)

38 (83%)

44 (80%)

60 (88%)

Neutral

20 (12%)

8 (17%)

10 (18%)

2 (3%)

Unlikely

7 (4%)

0 (0%)

1 (2%)

6 (9%)

  1. BPaL bedaquilline & pretomanid & linezolid, Fq fluoroquinolone, MDR multi-drug resistant, SoC standard of care, TB tuberculosis, XDR extensively drug-resistant